anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The present invention discloses a barbary wolfberry fruit glycopeptide and a production process thereof. The product of the barbary wolfberry fruit glycopeptide is in the form of powder prepared from the raw material of barbary wolfberry fruit, wherein the content of glucoprotein is from 70% to 90%. The production process comprises the steps of soaking, extraction, centrifugal separation, settlement to separate, ultrafiltration to purify, vacuum freezing to dry, etc. The product of the barbary wolfberry fruit glycopeptide provided by the present invention contains the glucoprotein with the strongest immunity activity and anti-senility effect among the known polysaccharide extracts at present. The barbary wolfberry fruit glycopeptide can effectively inhibit the proliferation of cancer cell and can effectively inhibit and obviously reduce the generation of lipid peroxide. The production process provided by the present invention has the advantages of simplicity and easy operation, and effective glucoprotein in barbary wolfberry fruit can be extracted in high efficiency.
Participants will be treated with the sham device (5% intensity) twice per day with an interval of at least 4 hours, each treatment last 3 minutes. Cross over arms after one month of use and one month of washout period.
The invention provides a drug for treating hepatocirrhosis ascites, and a preparation method thereof. The drug is composed of a drug A and a drug B, wherein the drug A is formed by combination of 20 medicinal materials such as unprocessed radix aconiti lateralis, radix aconite lateralis preparata, all-grass of cruciate buchnera, radix bupleuri, white peony root, radix ophiopogonis, rhizoma curcumae, rhizoma zingiberis, cortex cinnamomi, dahurian patrinia herb and the like. The above medicinal materials are pretreated by crushing or water decoction extraction, and then made into granules or capsules by adding an excipient. The drug B is formed by combination of 13 medicinal materials such as turtle shell, eaglewood, pseudo-ginseng, radix polygoni multiflori preparata, placenta hominis, ground beetle, red ginseng, amber and the like. The above medicinal materials are crushed and added with the excipient to form granules or capsules. The drug has novel formula, is simple in preparation process, is convenient for taking, has the functions of soothing the liver and strengthening the spleen, strengthening body resistance and eliminating blood stasis, promoting blood circulation to remove the blood stasis, inducing dieresis to remove moisture and relieving pains and expelling pus, can effectively recover liver function functions, enhances self immunity of a patient, increases urine flow, decreases ascites, has no toxic or side effect by taking the drug for a long time, and is suitable for popularization and application.
PROBLEM TO BE SOLVED: To obtain a new antimicrobial substance capable of exhibiting antimicrobial action even on disease-causing microorganisms against which the existing antimicrobial substance is not entirely effective. SOLUTION: This antimicrobial substance BE-65932 is a compound expressed by the formula or its pharmaceutically acceptable salt, and has the following physicochemical properties: (1) being white powder or solid; (2) having the molecular formula: C24 H31 O11 N5 ; (3) having a specific rotation [α]<20> D+71.4 (c 1.0, MeOH); (4) capability of easily dissolving in an organic solvent (e.g. methanol, dimethyl sulfoxide (DMSO), or the like) and water, and being difficult to dissolve in chloroform; (5) having basicity; (6) being positive in color reactions of test of readily carbonizable substances and phosphomolybdic acid reaction, or the like. The substance of the formula is obtained by incubating microorganisms belonging to Streptomyces and capable of producing the compound of the formula (pref. streptomyces sp.  A 65932 or its variant) and by collecting the compound of the formula from cultures, and is useful as an antimicrobial agent against disease caused by various kinds of microorganisms.
Two clinical trials were performed in a total of 88 patients who had suspected intra-abdominal infection or inflammation. Subjects received both Tc 99m labeled leukocytes and a radiolabeled comparator. Images were obtained at 2 and 30 minutes and at 2 and 4 hours and 24 hours. In two other clinical trials, in a total of 127 patients with suspected abdominal inflammation or infection received Tc 99m labeled leukocytes. Imaging was at 24 hours in one study and at 1, 3 and 24 hours in the other. In all four studies images were blindly evaluated and the findings were confirmed by surgery, biopsy or other clinical data.

Based on the above 4 studies, between 2 to 4 hours Tc 99m labeled leukocytes had 95-100% sensitivity and 62-85% specificity. In all studies, the false positive and false negatives relate to the bowel background, the location of the site of infection/inflammation and whether or not it is contiguous with the bowel. Images obtained at 24 hours can be unreliable because of a high bowel background; false negatives were noted in both Tc 99m and the radiolabeled comparator.

Other studies suggest that the interpretation of the images could be affected by the presence of tumors, infarction and peritonitis; liver abscess may be missed because of the bowel background.
Novel techniques are described for protocol tracking and/or enforcement (PT&E) of social distancing protocols in communication networks. For example, PT&E data can be received and aggregated from a large number of user mobile devices via wireless communication networks. The PT&E data can be analyzed against a pre-defined social distancing protocol to detect candidate non-compliance events. The social distancing protocol is stored in association with predefined exclusions to application of the social distancing protocol. The candidate non-compliance events can be analyzed against the predefined exclusions to determine whether the detected events are excluded from consideration as a non-compliant condition. The detected candidate non-compliance events and/or non-compliant conditions can then support various features, such as warning individuals and/or organizations of compliance concerns, contact tracing responsive to non-compliant conditions, compliance scoring for entities, social grading for individual compliance, heat mapping of compliance-related data, etc.
Surveys at baseline, 8 months (end 8th grade), 20 mo (end 9th grade), 28 mo (mid-10th grade). ATI-V prevention program training after 4th assessment - after 28 months.
This research involves ultrasounds of the heart by two different emergency medicine doctors who are residents in training. Results from the two doctors will be compared to see how similar they are. This research will help us understand if heart ultrasounds can be used to see how well the heart pumps blood and if similar results are obtained from different doctors.

The doctors will use ultrasound of the heart to measure E-Point Septal Separation (EPSS). EPSS is the distance between two parts of the heart, the mitral valve and the ventricular septum. EPSS is measured in millimeters (mm). EPSS can estimate left ventricular ejection fraction (LVEF) as a measure of how well the heart pumps blood.
Fenofibric acid delayed release capsules (fenofibric acid) are a lipid regulating agent available as delayed release capsules for oral administration. Each delayed release capsule contains choline fenofibrate, equivalent to 45 mg or 135 mg of fenofibric acid. The chemical name for choline fenofibrate is ethanaminium, 2-hydroxy-N,N,N-trimethyl, 2-{4-(4-chlorobenzoyl)phenoxy] -2-methylpropanoate (1:1) with the following structural formula:

The empirical formula is C22H28ClNO5 and the molecular weight is 421.91. Choline fenofibrate is freely soluble in water. The melting point is approximately 210°C. Choline fenofibrate is a white to yellow powder, which is stable under ordinary conditions.

Each delayed release capsule contains enteric coated mini-tablets comprised of choline fenofibrate and the following inactive ingredients: hypromellose, povidone, water, hydroxypropyl cellulose, colloidal silicon dioxide, sodium stearyl fumarate, methacrylic acid copolymer, talc, triethyl citrate. The capsule shell of the 45 mg capsule contains the following inactive ingredients: gelatin, titanium dioxide, yellow iron oxide, black iron oxide, and red iron oxide. The capsule shell of the 135 mg capsule contains the following inactive ingredients: gelatin, titanium dioxide, yellow iron oxide, and FD&C Blue #2.
Patients with moderate or severe disease who presented to HFHS within the first week of the COVID epidemic in Detroit were initially treated with supportive care with or without a combination of lopinavir-ritonavir and ribavirin or hydroxychloroquine according an institutional guideline developed by Infectious Diseases Physicians and Pharmacists. The institutional guidelines were developed by consensus, and based on the available literature, experience from Wuhan, China and other centers around the world affected by COVID-19 before Michigan. Intravenous (IV) remdesivir compassionate use was requested for eligible mechanically ventilated patients. On March 17, 2020 lopinavir-ritonavir with ribavirin was removed from the COVID-19 institutional protocol.
At treating physician's discretion, one of the following, or a combination of the following, will be administered to the patient: Amiodarone, beta blockers or non-dihydropyridine calcium channel blockers, digoxin. The target heart rate is less than 120 beats per minute (bpm) or maintained hemodynamics. Patients in the rate-control arm who are hypotensive after new onset atrial fibrillation can undergo DCC at the provider's discretion and crossover into the rhythm-control arm.
Arm 1 (Interventional) : Respondent has given bread with composit flour and vla with dadiah. pregnant women received 1 pieces bread containing 50 gram provide total fat 4 gram, protein 5 gram, carbohydrate 23.8 gram, Fe 2 mg, 2150 kcal and vla dadiah containing 30 gram provide 308 kcal.
The purpose of this study is to evaluate the effect of sitagliptin on gastric emptying, intragastric meal distribution, postprandial glycemia and insulinemia in healthy subjects. Glucagon-like peptide-1 (GLP-1) inhibits gastric emptying, thereby slowing the delivery of nutrients, and their absorption, across the small intestine. The rate of entry of carbohydrate into the small intestine is especially important in patients with diabetes mellitus. Sitagliptin is an orally administered inhibitor of dipeptidyl-peptidase-IV (DPP-IV), the enzyme responsible for the degradation of GLP-1. It is hypothesized that sitagliptin will increase the GLP-1 response to, and thereby slow gastric emptying and diminish the glycemic response to, a carbohydrate-containing meal.

Fifteen healthy subjects (male and female) will be studied. Each subject will be studied on two occasions following treatment for 2 days with sitagliptin (100mg once daily) or matching placebo in a randomized, double blind, crossover design. Measurements of gastric emptying, intragastric meal distribution, blood glucose concentrations, gut hormones and appetite will be measured for 4 hours following ingestion of a mashed potato meal.
Participants in the active-control group will undergo a 5-week program that only involves interactions with horses without any clinical input (i.e. commonly coined as animal-assisted activities).
Subjects randomized to observation will only have physical therapy assessment using the Berg Balance Test and 6min Walk Test at baseline and end point. These subjects will not receive any exercise teaching.
Each subject will undergo laparoscopic sleeve gastrectomy, as part of their clinical care. This is a single-arm study, in which the investigators collect data prior to the procedure, 3 months after the procedure, and 12 months after the procedure.
906,580. Centrifugal pumps. CIBA Ltd. June 20, 1961 [June 23, 1960], No. 22283/61. Class 110 (1). Apparatus for pumping a liquid from a container comprises a vessel within which is enclosed a centrifugal pump, the suction side of which communicates with the interior of the vessel, a pressure pipe extending upwardly from the vessel and communicating with the pressure side of the pump, a suction pipe which opens in the vessel near the bottom thereof, has an elbow bend above the top of the vessel and extends downwardly for delivering liquid from a container to the vessel, and a narrow passage affording communication between the elbow bend and the portion of the pressure pipe extending upwardly from the level of the elbow bend. The centrifugal pump depends from a cover-plate 12 for a container (not shown) for the liquid to be pumped. A motor (not shown) mounted above the cover-plate 12 drives the pump through a shaft 34 passing through a tube 36 which extends beyond the highest level of the liquid in the container. The centrifugal pump is immersed in a vessel 18 which communicates with the interior of the container through a suction pipe 20 having an extension (not shown) which terminates close to the bottom of the container. Initially, the liquid in the suction pipe 20 and a pressure pipe 24 is at the level 52 and the vessel 18 is full. When the pump is started, it draws liquid from the vessel 18 through an inlet 33 and delivers it to the pressure pipe 24. The resultant reduction of pressure at the top of the vessel 18 causes liquid to be drawn out of the container through the suction pipe 20. When this liquid has reached the elbow bend 48, priming of the pump is complete and the liquid in the vessel 18 has fallen to the level 54. Since the outlet opening 44 of the suction pipe 20 is below this level (and advantageously at a higher level than the pump inlet 33), the formation of foam or bubbles due to entrainment of air is prevented. To accelerate the priming, the suction pipe 20 may communicate with the upper part of the vessel 18 through a narrow bore. When the pump is stopped, the liquid in the pressure pipe 24 runs back through the vessel 18 and the suction pipe 20 into the container until it reaches the level of an anti-siphoning conduit 50. Air then passes through the conduit 50 to the suction pipe 20 to break the siphon and the liquid level is stabilized at 52. Specification 864,620 is referred to.
PURPOSE: An agent containing glycerol glycolipid compounds for preventing and treating influenza diseases is provided to ensure excellent antiviral effect in vivo and in vitro and to be used in a veterinary composition, feed additives, and anti-viral disinfection composition for preventing and treating animal diseases caused by viral infection. CONSTITUTION: A glycerol glycolipid compound is denoted by chemical formula 1 or 2. A pharmaceutical composition for preventing and treating influenza diseases contains the glycerol glycolipid compounds and a pharmaceutically acceptable carrier. The influenza diseases are caused by influenza virus A. A composition for preventing and treating influenza virus diseases contains a fat-soluble extract of green tea as an active ingredient. The fat soluble extract is prepared by hexane or dichloromethane. A veterinary composition for preventing and treating the influenza diseases contains the glycerol glycolipid compounds. A feed additive composition contains the glycerol glycolipid compounds.
Chronic low back pain (cLBP) is a major cause of disability and healthcare expenditure worldwide. Its prevalence is increasing globally from somatic and psychosocial factors. While non-pharmacological management, and in particular physiotherapy, has been recommended as a first-line treatment for cLBP, it is not clear what type of physiotherapeutic approach is the most effective in terms of pain reduction and function improvement. This analysis is rendered more difficult by the vast number of available therapies and a lack of a widely accepted classification that can effectively highlight the differences in the outcomes of different management options. This study was conducted according to the PRISMA guidelines. In January 2024, the following databases were accessed: PubMed, Web of Science, Google Scholar, and Embase. All the randomised controlled trials (RCTs) which compared the efficacy of physiotherapy programs in patients with cLBP were accessed. Studies reporting on non-specific or mechanical cLPB were included. Data concerning the Visual Analogic Scale (VAS) or numeric rating scale (NRS), Roland Morris Disability Questionnaire (RMQ) and Oswestry Disability Index (ODI). Data from 12,773 patients were collected. The mean symptom duration was 61.2 ± 51.0 months and the mean follow-up was 4.3 ± 5.9 months. The mean age was 44.5 ± 9.4 years. The mean BMI was 25.8 ± 2.9 kg/m2. The Adapted Physical Exercise group evidenced the lowest pain score, followed by Multidisciplinary and Adapted Training Exercise/Complementary Medicine. The Adapted Physical Exercise group evidenced the lowest RMQ score followed by Therapeutic Exercises and Multidisciplinary. The Multidisciplinary group evidenced the lowest ODI score, followed by Adapted Physical Exercise and Physical Agent modalities. Within the considered physiotherapeutic and non-conventional approaches to manage nonspecific and/or mechanic cLBP, adapted physical exercise, physical agent modalities, and a multidisciplinary approach might represent the most effective strategy to reduce pain and disability.
FIELD: veterinary science, production and application of biological products, vaccination, prophylaxis. SUBSTANCE: an associated vaccine is prepared from anthrax strain of 55-VNIIVViM at final concentration being 2.0-2.5 x 1010 9  spores per 1 cmcm 3  and vaccinal strain of emphysematous carbuncle 2/14 at final concentration being 2.0-2.1 x 1010 9  cells per 1 cmcm 3 . For prophylaxis of anthrax and emphysematous carbuncle in farm animals it is necessary to use an associated vaccine which contains the above mentioned strains. The given vaccine should be introduced subcutaneously in area of the middle third of a neck in cattle aged within 3-6 months at the dose of 1.0-1.1 cmcm 3 , aged above 6 months - 2.0-2.1 cmcm 3 . EFFECT: the given vaccine is of higher immunogenicity, it is also areactogenous and safe to create more prolonged and tense immunity both to anhrax and emphysematous carbuncle in cattle. 2 cl, 2 tbl
INTRODUCTION: Surgical stabilization of rib fractures (SSRF) has been associated with lower rates of mortality and fewer respiratory complications. This study sought to evaluate the association between SSRF timing and patient outcomes.
METHODS: This retrospective analysis included patients aged ≥45 y who underwent SSRF in the Trauma Quality Improvement Program database from 2016 to 2020. Primary outcome was incidence of ventilator-assisted pneumonia (VAP). Secondary outcomes included acute respiratory distress syndrome (ARDS), unplanned endotracheal intubation, in-hospital mortality, failure to rescue (FTR) after all major complications, and FTR after severe respiratory complications. Logistic regression models of outcomes on timing to SSRF were fit while controlling for age, gender, body mass index, injury severity score, flail chest, chronic obstructive pulmonary disease, congestive heart failure, and smoking.
RESULTS: Among 4667 patients who received SSRF, average time to SSRF was 4.6 ± 3.2 d. Each additional day to SSRF was associated with increased odds of VAP (odds ratio [OR] 1.07, confidence interval [CI] 1.03-1.11) and intubation (OR 1.10, CI 1.08-1.13). A longer time to SSRF was associated with increased odds of ARDS (OR 1.10, CI 1.05-1.15), while no significant association was observed for in-hospital mortality (OR 0.99, CI 0.93-1.04). A longer time to SSRF was associated with decreased odds of FTR after a major complication (OR 0.90, CI 0.83-0.97) and respiratory complications (OR 0.87, CI 0.78-0.96).
CONCLUSIONS: For each day that SSRF is delayed, increased odds of VAP, intubation, and ARDS were observed. Prompt intervention is crucial for preventing these complications and improving our ability to rescue patients.
Electrical stimulation therapy with the OkuStim System can help patients with retinitis pigmentosa and other hereditary retinal diseases slow the progression of visual field defects and thus preserve usable vision for longer. Since degenerative processes in the retina also lead to loss of vision in patients with glaucoma, the desired clinical benefit in this group of patients is also to slow down the decline in the visual field.

This is a prospective, single-center, randomized, sham-controlled, double-masked pilot study in a parallel group design. Patients are assigned 1:1 to one of two different groups: Sham group (sham treatment) or TES with maximum tolerated current intensity below the pain threshold (tolerance threshold). Patients are stimulated in one eye (study eye). Since these are patients with progressive visual field defects and the experimental therapy is being compared with a sham treatment, the patients also receive pressure-lowering eye drops ("treatment as usual", "TAU") to ensure the safety of the study participant. Treatment duration is 18 months for each patient, with application of TES once a week for 30min.
BACKGROUND: Impaired left atrial (LA) strain predicts atrial fibrillation (AF) recurrence after catheter ablation (CA), but currently there is no cut-off to guide patient selection for CA. Integrated backscatter (IBS) is a promising tool for noninvasive quantification of myocardial fibrosis. The aim of this study was to compare LA strain and IBS between paroxysmal, persistent, and long-standing persistent AF and evaluate their association with AF recurrence after CA.
METHODS: Analysis of consecutive patients with symptomatic paroxysmal and persistent AF who underwent CA. LA phasic strain, strain rate and IBS were assessed by two-dimensional speckle-tracking at baseline.
RESULTS: We analyzed 78 patients, 31% with persistent AF (46% long-standing AF), 65% male, mean age 59 ± 14 years, who underwent CA and were followed-up for 12 months. AF recurrence occurred in 22 (28%) patients. LA phasic strain parameters were significantly impaired in patients with AF recurrence and were independent predictors of AF recurrence in a multivariable analysis. LA reservoir strain (LASr) < 18% predicted AF recurrence with 86% sensitivity and 71% specificity, with a higher predictive power compared to LA volume index (LAVI). LASr < 22% in paroxysmal AF and LASr < 12% in persistent AF correlated with AF recurrence. Increased IBS was a predictor of AF recurrence in patients with paroxysmal AF.
CONCLUSION: LA phasic strain parameters were predictors of AF recurrence after CA, independently of LAVI and AF subtype. LASr < 18% showed a higher predictive power compared to LAVI. Further studies are needed to investigate the role of IBS as a predictor of AF recurrence.